MX2016002027A - Nuevos anticuerpos anti receptores iib fc-gama y usos de los mismos. - Google Patents

Nuevos anticuerpos anti receptores iib fc-gama y usos de los mismos.

Info

Publication number
MX2016002027A
MX2016002027A MX2016002027A MX2016002027A MX2016002027A MX 2016002027 A MX2016002027 A MX 2016002027A MX 2016002027 A MX2016002027 A MX 2016002027A MX 2016002027 A MX2016002027 A MX 2016002027A MX 2016002027 A MX2016002027 A MX 2016002027A
Authority
MX
Mexico
Prior art keywords
novel anti
gamma receptor
antibodies
receptor iib
iib antibodies
Prior art date
Application number
MX2016002027A
Other languages
English (en)
Inventor
Peter Sondermann
Meer Dominik Ter
Thomas Pohl
Anna Carle
Daniela Ehehalt
Nicole Rieth
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of MX2016002027A publication Critical patent/MX2016002027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)

Abstract

La presente invención proporciona anticuerpos anti- Fc?Rllb que, en comparación con los anticuerpos de la técnica anterior, incrementan notablemente la fosforilación ITIM de Fc?Rllb y por lo tanto pueden ser utilizados para el tratamiento o profilaxis de enfermedades autoinmunes.
MX2016002027A 2013-08-16 2014-08-13 Nuevos anticuerpos anti receptores iib fc-gama y usos de los mismos. MX2016002027A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13004094.2A EP2837637A1 (en) 2013-08-16 2013-08-16 Novel anti-FcyRIIB IgG-type antibody
PCT/EP2014/002234 WO2015022077A1 (en) 2013-08-16 2014-08-13 Novel anti-fc-gamma receptor iib antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2016002027A true MX2016002027A (es) 2016-05-16

Family

ID=49000296

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002027A MX2016002027A (es) 2013-08-16 2014-08-13 Nuevos anticuerpos anti receptores iib fc-gama y usos de los mismos.

Country Status (24)

Country Link
US (1) US10407499B2 (es)
EP (2) EP2837637A1 (es)
JP (2) JP6775420B2 (es)
KR (1) KR102385790B1 (es)
CN (1) CN105636987B (es)
AU (1) AU2014308143B2 (es)
BR (1) BR112016003030A2 (es)
CA (1) CA2921251C (es)
CL (1) CL2016000349A1 (es)
DK (1) DK3033357T3 (es)
EA (1) EA035855B1 (es)
ES (1) ES2668482T3 (es)
HK (1) HK1224302A1 (es)
HR (1) HRP20180664T1 (es)
HU (1) HUE038977T2 (es)
IL (1) IL244135B (es)
MX (1) MX2016002027A (es)
MY (1) MY174711A (es)
NO (1) NO3033357T3 (es)
PL (1) PL3033357T3 (es)
PT (1) PT3033357T (es)
SG (1) SG11201600930RA (es)
SI (1) SI3033357T1 (es)
WO (2) WO2015022076A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) * 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN106795223B (zh) 2014-08-13 2021-05-04 苏伯利莫尔公司 针对Fcγ受体IIB及Fcε受体的抗体
KR20210004994A (ko) * 2018-03-26 2021-01-13 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US20050260213A1 (en) * 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof
DK1534335T4 (en) * 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2005018669A1 (en) * 2003-08-18 2005-03-03 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
PT1709073E (pt) 2003-11-26 2011-09-29 Max Planck Gesellschaft Substância que se liga ao receptor fc iib de igg humano (fcgamariib)
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
ATE499384T1 (de) 2005-12-13 2011-03-15 Suppremol Gmbh Multimere fc-rezeptor-polypeptide
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
ES2556214T3 (es) 2007-11-12 2016-01-14 U3 Pharma Gmbh Anticuerpos para AXL
EP2234641B1 (en) * 2008-01-03 2015-08-19 Genmab A/S Monoclonal antibodies against cd32b
EP2623112B1 (en) 2008-06-27 2015-03-04 Zymogenetics, Inc. Soluble hybrid Fc gamma receptors and related methods
US10028998B2 (en) 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
US10669324B2 (en) 2012-10-30 2020-06-02 Suppremol Gmbh Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN106795223B (zh) 2014-08-13 2021-05-04 苏伯利莫尔公司 针对Fcγ受体IIB及Fcε受体的抗体

Also Published As

Publication number Publication date
WO2015022077A1 (en) 2015-02-19
CN105636987A (zh) 2016-06-01
EP3033357B1 (en) 2018-02-14
HUE038977T2 (hu) 2018-12-28
ES2668482T3 (es) 2018-05-18
EP3033357A1 (en) 2016-06-22
HRP20180664T1 (hr) 2018-07-13
KR20160036631A (ko) 2016-04-04
AU2014308143B2 (en) 2019-10-31
AU2014308143A1 (en) 2016-03-03
CA2921251C (en) 2023-01-24
NO3033357T3 (es) 2018-07-14
JP2016530256A (ja) 2016-09-29
IL244135A0 (en) 2016-04-21
BR112016003030A2 (pt) 2017-09-12
US20160185857A1 (en) 2016-06-30
WO2015022077A8 (en) 2015-12-03
CA2921251A1 (en) 2015-02-19
PL3033357T3 (pl) 2018-08-31
EP2837637A1 (en) 2015-02-18
HK1224302A1 (zh) 2017-08-18
SG11201600930RA (en) 2016-03-30
DK3033357T3 (en) 2018-05-22
JP6775420B2 (ja) 2020-10-28
JP2020048562A (ja) 2020-04-02
KR102385790B1 (ko) 2022-04-12
EA201690383A1 (ru) 2016-06-30
US10407499B2 (en) 2019-09-10
IL244135B (en) 2020-02-27
MY174711A (en) 2020-05-10
EA035855B1 (ru) 2020-08-20
CN105636987B (zh) 2020-07-31
WO2015022076A1 (en) 2015-02-19
CL2016000349A1 (es) 2016-11-04
PT3033357T (pt) 2018-05-18
SI3033357T1 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12016501763A1 (en) Multispecific antibodies
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
PH12016501700A1 (en) Combination therapies with anti-cd38 antibodies
PH12017502180A1 (en) Tau-binding antibodies
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX2015012334A (es) Metodos y composiciones para el control de malezas.
MX2016001093A (es) Nanoemulsion de aminosilicona.
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
MX2016001094A (es) Nanoemulsion de aminosilicona.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
PH12017502207A1 (en) Tau-binding antibodies
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
IN2014DN05885A (es)
MX2017007491A (es) Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
IN2013MU00848A (es)
MX2016002027A (es) Nuevos anticuerpos anti receptores iib fc-gama y usos de los mismos.
IN2013MU01113A (es)
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
NZ721832A (en) Solid forms of tenofovir
MX2015010789A (es) Anticuerpos anti-pcsm.
IN2013MU03768A (es)

Legal Events

Date Code Title Description
FG Grant or registration